- NEWS AND VIEWS
Severe hepatitis outbreak in children linked to AAV2 virus
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Rent or buy this article
Get just this article for as long as you need it
Prices may be subject to local taxes which are calculated during checkout
Nature 617, 471-472 (2023)
Alexander, E. C. & Deep, A. JAMA Netw. Open 5, e2237091 (2022).
Ho, A. et al. Nature 617, 555–563 (2023).
Morfopoulou, S. et al. Nature 617, 564–573 (2023).
Servellita, V. et al. Nature 617, 574–580 (2023).
Gutierrez Sanchez, L. H. et al. N. Engl. J. Med. 387, 620–630 (2022).
Kelgeri, C. et al. N. Engl. J. Med. 387, 611–619 (2022).
Karpen, S. J. N. Engl. J. Med. 387, 656–657 (2022).
Sant’Anna, T. B. & Araujo, N. M. Virol. J. 19, 173 (2022).
Shen, W., Liu, S. & Ou, L. Front. Immunol. 13, 1001263 (2022).
Brevini, T. et al. Nature 615, 134–142 (2022).
F.T.’s laboratory has received research funding at Charité – Universitätsmedizin Berlin from Allergan, Bristol Myers Squibb, Gilead and Inventiva. F.T. has acted as a consultant for AstraZeneca, Allergan, Bayer, Boehringer Ingelheim, Galapagos, Gilead, Intercept, Inventiva, Madrigal, Novartis, Novo Nordisk and Pfizer.